Acer Therapeutics (Acer Therapeutics) Total Inventories : $4.60 Mil (As of Jun. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Acer Therapeutics Total Inventories?

Acer Therapeutics's total inventories for the quarter that ended in Jun. 2023 was $4.60 Mil. Acer Therapeutics's average total inventories from the quarter that ended in Mar. 2023 to the quarter that ended in Jun. 2023 was $2.51 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Acer Therapeutics's Net-Net Working Capital per share for the quarter that ended in Jun. 2023 was $-1.80.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year. Acer Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2023 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Acer Therapeutics Total Inventories Historical Data

The historical data trend for Acer Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acer Therapeutics Total Inventories Chart

Acer Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Inventories

Get a 7-Day Free Trial

Acer Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Inventories	Get a 7-Day Free Trial															-	-	-	0.41	4.60

Acer Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Acer Therapeutics (OTCPK:ACER) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Acer Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2023 is

	Net-Net Working Capital Per Share (Q: Jun. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1.553	+	0.75 * 0	+	0.5 * 4.601	-	47.894
-	0	-	0)	/	24.4637
=	-1.80

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Acer Therapeutics's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Jun. 2023 )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
	=	2.5065	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Acer Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Jun. 2023 )	/	Average Total Inventories (Q: Jun. 2023 )
	=	0	/	2.5065
	=	0.00

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Acer Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	2.5065	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Acer Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Acer Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Acer Therapeutics (Acer Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acer Therapeutics Inc (OTCPK:ACER) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Washington Street, One Gateway Center, Suite 351, Newton, MA, USA, 02458

Website

https://www.acertx.com

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

Executives

Chris Schelling	director, officer: President and Chief Executive	C/O ACER THERAPEUTICS INC., 222 THIRD STREET, CAMBRIDGE MA 02142
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Tanya Hayden	officer: Chief Operating Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Adrian W Quartel	officer: Chief Medical Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Bernard H Paul	officer: Chief People Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
Jefferson E Davis	officer: Chief Business Officer	300 WASHINGTON STREET, ONE GATEWAY CENTER, SUITE 351, NEWTON MA 02458
John Michael Dunn	director	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Donald Joseph	officer: Chief Legal Officer and Secy	C/O KALOBIOS PHARMACEUTICALS, INC., 260 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Michael Klopp	officer: Chief Technology Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Matthew Seibt	officer: Chief Commercial Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Harry S Palmin	officer: Chief Opp. and Financial Offr	C/O NOVELOS THERAPUETICS, INC., ONE GATEWAY CENTER,SUITE 504, NEWTON MA 02458
William T. Andrews	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Jason Amello	director	500 KENDALL STREET, CAMBRIDGE MA 01824
Salma Jutt-eghbali	officer: Chief Commercial Officer	ONE GATEWAY CENTER, SUITE 351, 300 WASHINGTON STREET, NEWTON MA 02458